Vedanta Biosciences
Financing Rounds
- Series C
- Series D+
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy.
View Website
Modality
- Biologic
Indications
- Gastroenterology
- Immunology & Inflammation
- Infectious Disease
- Oncology
Development Status
- Phase 2